Effect of insulin and alendronate sodium on bone transition and bone mineral density in aged patients with newly diagnosed type 2 diabetes mellitus with osteoporosis. (English)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Objective To observe the intervention of insulin and alendronate sodium, and to investigate the changes of bone specificity alkaline phospha-tase (BAP), tartrateresistant acid phosphatase-5b (TRAP-5b), osteocalcin (BGP), and the bone mineral density ( BMD) of the femur neck in diabetes patients with osteoporosis after 12-month treatment. Methods One hundred and twenty-eight senile patients with osteoporosis, who were treated in our hospital, were selected and randomly divided into 4 groups; control group (METF), insulin group (INSU), metformin + alendronate sodium group (METF + ALEN), and insulin + alendronate sodium group (INSU + ALEN). At the same time, Caltrate D was given as a basic treatment. BMD of the femoral neck and the serum levels of BAP, BGP, and TRAP-5b were detected before the treatment and 12 months after the treatment. And the results were analyzed. Results After 12-month treatment, BMD in INSU + ALEN group increased compared with that before the treatment (P < 0. 05), while no significant change in METF group and INSU group was observed (P > 0. 05). BMD of the femoral neck in METF + ALEN group increased slighthly without significant difference (P > 0. 05). BMD in INSU + ALEN group increased more significantly compared with that in other groups (P < 0. 05). After 12-month treatment, the levels of BAP and BGP in INSU + ALEN group increased obviously, while the level of TRAP-5b decreased significantly (P < 0. 05 ). Compared with that in control group and other treatment groups, the difference was significant (P < 0. 01). In METF group, INSU group, and METF + ALEN group, the serum levels of BAP and BGP increased slightly after 12-month treatment, while serum TRAP-5b level decreased slightly (P > 0. 05). Conclusion Insulin is the first choice in the treatment of diabetes mellitus-induced osteoporosis, which can increase bone mass and prevent bone from loss. Alendronate sodium can inhibit bone resorption, promote bone formation, retard the bone mass loss, and raise BMD. The combination of both drugs can prevent and treat diabetes mellitus-induced osteoporosis effectively. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)